epogen

Receive alerts:
by e-mail
E-mail Your information will be added to a database with the sole purpose of serving your subscription. This database is the exclusive property of vLex Networks S.L. and will never be shared with any other company. By sending your request you accept the Data Protection Policy of vLex Networks S.L. I have read and accept the Terms of Use
via RSS

8 documents for epogen

- Claim Interpretation Under The EPC - The UK House Of Lords Decision In Kirin-Amgem V Hoechst Marion Roussel
... the essential difference between Amgen's Epogen and the GA-EPO of TKT was that the former was made...
- --Amgen Gets a+ From S&P for Wksi Shelf
BANKING AND CREDIT NEWS-March 14, 2011 (C)2011 M2 COMMUNICATIONS http://www.m2.com

... of its key best-selling drugs - - Aranesp/Epogen, Neupogen/Neulasta, and Enbrel, accounting for alm...
- M2 Banking & Credit News
- May 27, 2011
- Sandoz GmbH v Roche Diagnostics GmbH, Court of Appeal - Chancery Division, July 28, 2004, [2004] EWHC 1313 (Ch)
... listed in the PDR at the time was Amgen's EPOGEN which was produced as a single dose vial containin...
- Kirin-Amgen Inc and others (Appellants) v. Hoechst Marion Roussel Limited and others (Respondents). Kirin-Amgen Inc and others (Respondents) v. Hoechst Marion Roussel Limited and others (Appellants) (Conjoined Appeals), (2004)
...Amgen market it under the name Epogen and the patent (which will expire on 11 December 2...
- House of Lords
- Kirin-Amgen Inc and others (Appellants) v. Hoechst Marion Roussel Limited and others (Respondents). Kirin-Amgen Inc and others (Respondents) v. Hoechst Marion Roussel Limited and others (Appellants) (Conjoined Appeals), (2004)
...Amgen market it under the name Epogen and the patent (which will expire on 11 December 2...
- House of Lords